Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

Cocco, Eleonora;
2022-01-01

Abstract

Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.
2022
2022
Inglese
JAMA NEUROLOGY
79
9
869
878
10
WOS:000832648700005
2-s2.0-85134987879
35877104
Esperti anonimi
internazionale
scientifica
Adult
Disease Progression
Female
Humans
Recurrence
Retrospective Studies
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis, Relapsing-Remitting
Goal 3: Good health and well-being
no
Portaccio, Emilio; Fonderico, Mattia; Iaffaldano, Pietro; Pastò, Luisa; Razzolini, Lorenzo; Bellinvia, Angelo; De Luca, Giovanna; Ragonese, Paolo; Pat ...espandi
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
32
none
Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie